Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | genetic association 0.05 (overall 0.03) | 0.05 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 6578
Sealed predictions
- SLC30A7 in dopamine neurons, braak-0.05 (p 0.894) → +0.56 (p 0.116)receipt 6586
Swarm cases
receipt 6586: SLC30A7 in dopamine neurons, braak
- power
- full sample +0.25 (p 0.319, n 18), 95% CI -0.25 to +0.64. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.28 (p 0.269, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.25 (p 0.310, n 18). could be the mix.
- skeptic
- leave-one-out range +0.17 to +0.41, sign flips 0; without severely affected donors +0.25 (p 0.319, n 18). fragile.
- cell type
- strongest in oligodendrocytes: +0.72 (p 7.8e-4, n 18) vs +0.25 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SLC30A7 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up SLC30A7 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.65 p 0.021 (needs p < 3.1e-4)
Receipts
loading the receipts